IRONWOOD PHARMACEUTICALS, INC.

Consensus Ironwood Pharmaceuticals, Inc.

Stocks

IRWD

US46333X1081

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 10/09/2026 BST			5-day change	1st Jan Change
3.970 ^USD	-2.46%		-7.46%	+17.80%

08-06	Ironwood Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06	Ironwood Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2026	CI

Evolution of the Average Target: Ironwood Pharmaceuticals, Inc.

Evolution of the Target Price: Ironwood Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Ironwood Pharmaceuticals, Inc.

7d6469b98ce97421e2b.0pR8CXBZVgvnVh0fl2mzK9Ds72LuupQU1ct8PyIEoG0.gKAEVkMBFGSqFXhRxwrGepjVowa79vBbuP0pRxpK6lWV4E9CQQATWpQzcg~be37049fa420637926cfa5f5b1f2ca19

Analysts' recommendations: Ironwood Pharmaceuticals, Inc.

11-05	AbbVie, Ironwood Win FDA Approval for Linzess to Treat Children With Irritable Bowel Syndrome With Constipation	MT
07/08/25	Ironwood Pharmaceuticals Q2 revenue beats expectations	RE
15/04/25	Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7	MT
15/04/25	Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8	MT
09/09/24	Leerink Partners Initiates Coverage on Ironwood Pharmaceuticals With Market Perform Rating, $5 Price Target	MT
16/02/24	Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating	MT
17/01/24	Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target	MT
28/09/23	JMP Securities Starts Ironwood Pharmaceuticals at Market Outperform, $22 Price Target	MT
23/05/23	Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating	MT
02/09/22	Capital One Securities Initiates IRWD at Overweight with $15 Price Target	MT
16/08/22	Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains Equalweight Rating	MT
22/04/22	Piper Sandler Starts Ironwood Pharmaceuticals at Overweight With $16 Price Target	MT
12/10/21	Ironwood Pharmaceuticals : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $14 From $13, Maintains Equal-Weight Rating	MT
16/07/21	Ironwood Pharmaceuticals : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $12 From $11, Maintains Equal-Weight Rating	MT
06/11/20	Ironwood Pharmaceuticals : Morgan Stanley Adjusts Ironwood Pharmaceuticals' Price Target to $12 from $11, Keeps Equalweight Rating	MT
06/11/20	Ironwood Pharmaceuticals : Credit Suisse Adjusts Ironwood Pharmaceuticals' Price Target to $12 From $11, Maintains Neutral Rating	MT

More recommendations

Specialty & Advanced Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IRONWOOD PHARMACEUTICALS, INC.					+53.65%
	MERCK & CO., INC.					+5.44%
	MERCK KGAA					+17.14%
	HALOZYME THERAPEUTICS, INC.					-6.96%
	KYOWA KIRIN CO., LTD.					+3.44%
	SK BIOPHARMACEUTICALS CO., LTD.					+56.28%
	YUHAN CORPORATION					+48.51%
	BETTA PHARMACEUTICALS CO., LTD.			-	-	-12.96%
	SUPERNUS PHARMACEUTICALS, INC.					+48.12%
	Average					+23.63%
	Weighted average by Cap.					+7.90%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

4

Last Close Price

3.970USD

Average target price

6.100USD

Spread / Average Target

+53.65%

High Price Target

10.00USD

Spread / Highest target

+151.89%

Low Price Target

3.700USD

Spread / Lowest Target

-6.80%

Analyst Consensus Detail

Consensus revision (last 18 months)

Ratings

Trader

Investor

-

Global

-

Quality

-

ESG MSCI

BB

Stock Market
Stocks
IRWD Stock
Consensus Ironwood Pharmaceuticals, Inc.

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!